|  |  |
| --- | --- |
| **Supplementary Table 1**.**The detailed reimbursement guidelines for nucleos(t)ide analogs therapy by the National Health Insurance Service in the Republic of Korea** | |
| Clinical status | Criteria for reimbursement of nucleos(t)ide analogs therapy |
| HBeAg-positive CHB | Serum HBV-DNA ≥ 20,000 IU/mL & serum AST or ALT ≥ 80 U/mL |
| HBeAg-negative CHB | Serum HBV-DNA ≥ 2,000 IU/mL & serum AST or ALT ≥ 80 U/mL |
| Compensated Cirrhosis | Serum HBV-DNA ≥ 2,000 IU/mL |
| HCC or decompensated cirrhosis | Detectable serum HBV-DNA (≥ 20 IU/mL) |
| Abbreviations; HBeAg, hepatitis B e antigen; CHB, chronic hepatitis B, HBV, hepatitis B virus; AST, aspartate aminotransferase; ALT, alanine aminotransferase; HCC, hepatocellular carcinoma | |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Supplementary Table 2. The detailed features of HCC diagnosed during the follow-up (n=58)** | | | | | | |
| **BCLC stage** | **MVR group** | **LLV group** |  | **Treatment modality** | **MVR group** | **LLV group** | |
| 0 | 0 (0.0%) | 5 (13.8%) |  | Surgery/liver transplantation | 8 (36.4%) | 7 (19.4%) | |
| A | 16 (72.7%) | 27 (75.0%) |  | Local ablation | 9 (40.9%) | 21 (58.4%) | |
| B | 5 (22.8%) | 2 (5.6%) |  | TACE | 4 (18.2%) | 6 (16.6%) | |
| C | 1 (4.5%) | 2 (5.6%) |  | TACE plus radiotherapy | 1 (4.5%) | 1 (2.8%) | |
|  |  |  |  | Radiotherapy | 0 (0.0%) | 1 (2.8%) | |
| Abbreviations; HCC, hepatocellular carcinoma; BCLC, Barcelona Clinic Liver Cancer; MVR, maintained virological response; LLV, low-level viremia; TACE, trans-arterial chemo-embolization | | | | | | |